Novel markers for haemogenic endothelium and haematopoietic progenitors in the mouse yolk sac
Diez-Pinel G +3 more
europepmc +1 more source
Clonal haematopoiesis in cardiovascular disease: prognostic role and novel therapeutic target. [PDF]
Schuermans A, Honigberg MC.
europepmc +1 more source
IMPACT OF LEISHMANIA DONOVANI INFECTION ON EARLY EVENTS IN HAEMATOPOIESIS [PDF]
Ana Isabel Pinto
openalex
Resilient Calvarial Bone Marrow Supports Retinal Repair in Type 2 Diabetes
Skull bone (calvarium) marrow in diabetic mice stay structurally intact and keeps making blood cells, unlike the bone marrow of the leg bones. The skull marrow is exposed to cerebrospinal fluid (CSF), which contains protective molecules called oxysterols.
Bright Asare‐Bediako +16 more
wiley +1 more source
Iron trapping in macrophages reshapes the homeostasis of the haematopoietic system. [PDF]
Crisafulli L +12 more
europepmc +1 more source
Cell‐Free DNA‐Based Theranostics for Inflammatory Disorders
Summary on the dual potential of cfDNA as biomarkers and therapeutic targets for inflammatory disorders. Figure was created with BioRender.com. ABSTRACT Inflammatory disorders are characterized by immune‐mediated inflammatory cascades that can affect multiple organs.
Jiatong Li +7 more
wiley +1 more source
Murine limb ischaemia induces structural and functional remodelling of local and distant bone marrow
Eades L +15 more
europepmc +1 more source
Clonal disorders of clinical significance. A concept with important therapeutic implications. [PDF]
Lipsker D.
europepmc +1 more source
Migrasomes in Ischemic Stroke: Molecular Landscape and Pathophysiological Impact
Multi‐omics profiling of stroke patients exposes systemic molecular fingerprints of immune activation, oxidative stress and metabolic collapse. Complement and coagulation cascade, and cholesterol metabolism emerge as shared functional hallmarks of plasma migrasomes in stroke patients and migrasomes isolated from experimental stroke mice.
Huifen Zhou +16 more
wiley +1 more source
Correspondence on 'Characteristics of second primary malignancies following bispecific antibodies therapy' by Liang <i>et al</i>. [PDF]
Jin Y, Jin Y, Cui Y, Zheng R.
europepmc +1 more source

